Great Point Partners (GPP), a health care equity investment firm located in Greenwich, Connecticut. Formed in 2003, Great Point Partners has been named one of the most active health care investors by PitchBook. GPP invests in all sectors of the health care industry, including firms that research biomarkers for use in clinical trials.
Biomarkers are objective measurable signs and indications of a medical state observed from someone outside of the patient. Examples of biomarkers are blood pressure, temperature, respiration rate, pulse, or laboratory tests.
Biomarkers are being evaluated in clinical trials as a surrogate predictor of an endpoint. A surrogate endpoint is scientific evidence that a biomarker consistently predicts an outcome for the patient, whether it is of benefit or harm.
The use of biomarkers for surrogate endpoints is advantageous because it reduces the risk of harm to human subjects. If the biomarker is a surrogate endpoint, the researcher can stop the clinical trial before the subject is exposed to a harmful treatment. Biomarkers could also be used for smaller studies to reduce the number of people exposed to an experimental treatment.